Detect the Omicron variant of SARS-CoV-2 with Meridian Bioscience’s new antibody pair
A rapid antigen test provides a fast and reliable indication of the presence of the SARS-CoV-2 virus, the causative agent of Covid-19. A positive result of an antigen test is reliable, whereas a negative result does not completely rule out infection with the SARS-CoV-2 virus. The success of rapid tests is therefore limited by the sensitivity of the antibodies used.
Meridian Bioscience has developed a novel SARS-CoV-2 nucleocapsid monoclonal antibody pair that detects the conserved SARS-CoV-2 nucleoprotein domain highly specifically and does not cross-react with seasonal coronavirus strains. This pair of antibodies can be used to develop reliable rapid antigen tests. The SARS-CoV-2 nucleocapsid antibody pair consists of a capture and a detection antibody. New data from an FDA-approved lateral flow assay show that this antibody pair detects the Omicron variant (B.1.1.529) down to 1.31 x 102 PFU/mL and all other variants down to 1.88 x 102 PFU/mL in clinical samples. The antibody pair has been validated for use in lateral flow and ELISA assays, has over 95 % purity, and is already used in FDA EUA and CE-marked kits.
Please contact us for more information or visit our website at www.dunnlab.de.
Contact:
Dr. Stefan Paulusch Product Manager
Dunn Labortechnik GmbH Thelenberg 6 DE-53567 Asbach
Tel. +49 (0) 26 83 / 4 30 94 Fax +49 (0) 26 83 / 4 27 76
E-Mail: info@dunnlab.de Internet: www.dunnlab.de
Biocytogen Co Ltd
Draupnir Bio ApS